Industry News
Novogen's US subsidiary postpones Nasdaq IPO
Sydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, is to postpone its IPO on the Nasdaq national market. [ + ]
Innovation Dynamics earns financial services licence
Consulting firm Innovation Dynamics has added a new string to its bow, after being granted an Australian Financial Services licence by ASIC. [ + ]
LCT raises $3m from mainly US investors
Cell therapy company Living Cell Technologies (ASX:LCT) has raised more than AUD$3 million through a placement of ordinary shares to US shareholders and an Australian investor. [ + ]
Trials in measuring radiation doses accurately
Researchers have begun trials which will allow radiation doses in computed tomography (CT) scans to be estimated much more accurately.
[ + ]Narhex commences phase I HIV drug trial
Anti-viral drug developer Narhex Life Sciences (ASX:NLS) has commenced recruitment of healthy volunteers for the phase I clinical trial of its anti-HIV protease inhibitor drug DG17. [ + ]
HeartWare gets Austrian thumbs-up
Artificial heart firm HeartWare (ASX:HTW) has been granted its first regulatory approval to commence human implants of the HVAD left ventricular assist device from the Austrian Ministry of Health. [ + ]
NSW forum to explore research ethics review
The NSW government's health department is to run a series of forums to explain an ethical review of multi-centre research, including progress towards a model of single ethical and scientific review. [ + ]
Leroy Hood to consult for LabCorp
Systems biology guru Dr Leroy Hood has entered into a strategic consulting relationship with US molecular testing equipment specialist LabCorp. [ + ]
Biotech performance was tale of two halves in 2005: Intersuisse
Australian biotech stocks underperformed both the All Ordinaries and the Nasdaq Biotech Index in 2005, but the second half of the year was brighter with stocks gaining 23.2 per cent, according to the Intersuisse Biotechnology Index. [ + ]
Australian experts disappointed by Hwang findings
Australian stem cell research experts have spoken out, in a series of statements, of their disappointment in the wake of findings by an independent review panel that a team led by South Korean scientist Hwang Woo-suk fabricated research on potentially groundbreaking papers on embryonic stem cells. [ + ]
GroPep goes into phase I infertility trial
GroPep (ASX:GRO) has begun to recruit healthy women volunteers into a phase I trial of its infertility drug PV903, targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus. [ + ]
Bio-Layer in new US development deal
Brisbane based Bio-Layer, a wholly-owned subsidiary of SSH Medical (ASX:SSH), has entered into a development and marketing agreement with a US-based life sciences company for the use of its surface coating product Mix&Go. [ + ]
Epitan reveals milestones for $10m VC funding
Melbourne-based Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has entered into a funding agreement with international specialist fund Absolute Capital Management (ACM) to raise AUD$10 million over the next 18 months. [ + ]
Starpharma HIV drug gets on FDA fast track
The US Food and Drug Administration (FDA) has granted 'fast track' status to Melbourne drug developer Starpharma's (ASX:SPL) VivaGel. [ + ]
Gene patent study misleading
A report in Science journal relating to gene patenting claimed: "Nearly a fifth of all human genes have been patented, a study has found, leading to fears that research into diseases such as breast cancer, diabetes and obesity could be stifled."
[ + ]
